digoxin

plant-derived medication used in certain heart conditions

Uses your system voice; voice and rate in settings.

Q422222Snapshot

≈ 4 min read

Names in other languages

  • Polskidigoksyna
  • Portuguêsdigoxina
  • Englishdigoxin
  • 中文地高辛
  • 简体中文地高辛
  • 繁體中文地高辛
  • 中文地高辛
  • 中文地高辛
  • 中文地高辛

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Digoxin, sold under the brand name Lanoxin, among others, is a medication used to treat various heart conditions. Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. Digoxin is one of the oldest medications used in the field of cardiology.

It works by increasing myocardial contractility, increasing stroke volume and blood pressure, reducing heart rate, and somewhat extending the time frame of the contraction. Digoxin is taken by mouth or by injection into a vein. Digoxin has a half life of approximately 36 hours given at average doses in patients with normal renal function.

It is excreted mostly unchanged in the urine. Common side effects include breast enlargement with other side effects generally due to an excessive dose. These side effects may include loss of appetite, nausea, trouble seeing, confusion, and an irregular heartbeat.

Greater care is required in older people and those with poor kidney function. It is unclear whether use during pregnancy is safe. Digoxin is in the cardiac glycoside family of medications.

It was first isolated in 1930 from Grecian foxglove (Digitalis lanata). It is on the World Health Organization's List of Essential Medicines. In 2021, it was the 241st most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Overdose

In overdose, the usual supportive measures are needed. If arrhythmias prove troublesome, or malignant hyperkalemia occurs (inexorably rising potassium level due to paralysis of the cell membrane-bound, ATPase-dependent Na/K pumps), the specific antidote is antidigoxin (antibody fragments against digoxin, trade names Digibind and Digifab).

The mechanism of action for drugs such as Digibind and Digifab, used when adverse events occur with the use of digoxin, is that the FAB regions on the antibodies created against digoxin expedite the excretion of the drug into urine. Therefore, the amount of digoxin in the body decreases quickly as it gets excreted rapidly.

Pharmacomicrobiomics

The bacteria Eggerthella lenta has been linked to a decrease in the toxicity of digoxin. These effects have been studied through comparisons of North Americans and Southern Indians, in which a reduced digoxin metabolite profile correlates with E. lenta abundance. Further studies have also revealed an increase in digoxin toxicity when used alongside erythromycin or tetracycline, the researchers attributed this to the decrease in the E. lenta population.

Digoxin and cancer

Cardiac glycosides, particularly digoxin, have been conventionally used for treatment of common cardiac problems, mainly heart failure and cardiac arrhythmias. The interaction of digoxin and cancer has also been studied. Despite existence of numerous preclinical studies that investigated the anticancer effects of digoxin, there are no solid and conclusive results so far.

Several studies have suggested that digoxin may have anticancer properties, others not. Digoxin, as a cardiac glycoside, has a chemical structure basically similar to that of estradiol. Digoxin has the ability to bind oestrogen receptors, and therefore it has been proposed that it might increase the risk of oestrogen-sensitive breast and uterine cancers.

A large Danish study found a complicated picture, with slightly increased risk of breast cancer amongst women taking digoxin, but better prognostic features. The Nurses' Health Study found a similar slight increase of risk. Digoxin inhibits the proliferation of many cancerous cell lines in vitro, but its relevance to cancer in vivo remains unclear.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371893917 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.